Aptevo Therapeutics Inc.
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -70.66% | 38.94% | -- |
| Gross Profit | -- | -- | 70.66% | -38.94% | -- |
| SG&A Expenses | 69.00% | 21.71% | -11.88% | -10.42% | -21.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.98% | 3.35% | -7.20% | -0.03% | -20.55% |
| Operating Income | -45.98% | -3.35% | 7.20% | 0.03% | 20.55% |
| Income Before Tax | -47.99% | -5.46% | 6.23% | -1.87% | 19.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.99% | -5.46% | 6.23% | -1.87% | 19.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.99% | -5.46% | 6.23% | -6.93% | 19.47% |
| EBIT | -45.98% | -3.35% | 7.20% | 0.03% | 20.55% |
| EBITDA | -47.42% | -4.11% | 6.66% | -0.69% | 20.33% |
| EPS Basic | 99.38% | -- | -- | -- | -- |
| Normalized Basic EPS | 99.48% | -- | -- | -- | -- |
| EPS Diluted | 99.38% | -- | -- | -- | -- |
| Normalized Diluted EPS | 99.48% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 28,214.69% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 28,214.69% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |